Introduction
============

Colorectal cancer (CRC) is the third most frequent type of cancer worldwide ([@B4]). This scenario shows the importance to improve strategies for CRC prevention and early detection to decrease its incidence and mortality ([@B5]). CRC arises from a stepwise evolution of normal mucosa to precursor lesions and ultimately to a malignant tumor. The adenoma is the most commonly reported precursor lesion of CRC ([@B3]; [@B12]). However, alternative precursor lesions include the serrated polyp, which was recently described as a precursor lesion of CRC. Serrated polyps are known to be a heterogeneous group of colorectal lesions that include hyperplasic polyps (HPs), sessile serrated adenoma (SSA), traditional serrated adenoma (TSA) and mixed polyps. Clinically, HPs are the most common precursor serrated lesions of CRC ([@B15]). Serrated adenocarcinomas accounts for about 10% of all CRCs ([@B13]).

The classic genetic model for colorectal tumorigenesis is driven by the progressive accumulation of a series of critical mutations in cancer-related genes, such as APC and *KRAS* ([@B3]). Since the molecular alterations among serrated pathways are less understood, the *BRAF* gene has now emerged as a prevalent marker in this pathway ([@B15]). With the presence of these genetic alterations, molecular biomarkers have been widely proposed as a means of CRC screening and prevention ([@B10]).

Recently, hotspot somatic mutations in the *TERT* promoter region (c.-124bp G \> A and c.-146bp G \> A) have been described in several tumors, particularly skin, brain, thyroid and bladder cancers ([@B8]; [@B9]; [@B11]; [@B14]; [@B7]). The *TERT* gene encodes a telomerase reverse transcriptase, an essential protein for preserving telomere genomic integrity. These mutations result in the creation of new binding motif sites (GGAA) for ETS transcription factors, leading to an increase in *TERT* activity and subsequent telomere preservation ([@B8]; [@B9]). Additionally, these hotspot mutations have been associated with advanced tumor stages and poor prognosis for patients ([@B11]; [@B14]; [@B7]). Currently, only one study evaluated *TERT* mutation frequency in CRC, and no mutations were found in colorectal adenocarcinomas ([@B11]).

Herein, we investigated the frequency of *TERT* mutations in a series of Brazilian patients with colorectal precursor and cancer lesions. We analyzed 145 Brazilian patients from the Barretos Cancer Hospital. The clinico-pathological and molecular features of the patients were previously reported ([Table 1](#t1){ref-type="table"}) ([@B15]). All included patients were over 50 years old, with a mean age of 66 years (ranging from 51 -- 89), with similar frequency for both genders. Patients with known family history, hereditary CRC, or bowel inflammatory disease were excluded. All cases were reviewed by an expert pathologist and categorized according to the WHO classification. Tumor DNA was isolated from formalin-fixed paraffin-embedded (FFPE) tumor tissue, as previously reported ([@B15]). *TERT* promoter mutations were identified by PCR followed by direct sequencing as described elsewhere ([@B14]; [@B1]).

###### Clinicopathological and molecular features of all patients.

  Variables                                                     N     \%
  -------------------------------- ---------------------------- ----- ------
  Age                              66.0 y mean (range 51- 89)   145   \-
  Gender                           Female                       71    49.0
                                   Male                         74    51.0
  Histology                        Adenocarcinoma               42    29.0
                                   Adenoma polyps               50    34.5
                                   Serrated polyps              15    10.3
                                   Hyperplastic polyps          38    26.2
  Precursor Lesion Location        Right colon                  39    37.9
                                   Left colon                   64    62.1
  Carcinoma Location               Right colon                  24    57.1
                                   Left colon                   18    42.9
  Precursor Lesion Morphology      Polypoid                     83    81.4
                                   Non polypoid                 19    18.6
  Precursor Lesion Size (mm)       \< 10                        91    90.1
                                   ≥ 10                         10    9.9
  Precursor Lesion MSI Status      MSS                          96    96.0
                                   MSI-L                        4     4.0
                                   MSI-H                        0     0.0
  Carcinoma MSI Status             MSS                          35    83.3
                                   MSI-L                        2     4.8
                                   MSI-H                        5     11.9
  Precursor Lesion *KRAS* Status   MUT                          14    13.6
                                   WT                           89    86.4
  Precursor Lesion *BRAF* Status   MUT                          9     8.7
                                   WT                           94    91.3
  Carcinoma *KRAS* Status          MUT                          20    47.6
                                   WT                           22    52.4
  Carcinoma *BRAF* Status          MUT                          2     4.8
                                   WT                           40    95.2

MUT, mutated; WT, wild type; MSI-L, microsatellite instability low; MSI-H, microsatellite instability high; MSS, microsatellite stability.

Of the 145 samples analyzed, 22 were inconclusive due to poor quality/quantity of DNA. The evaluation of hotspot *TERT* promoter mutations showed that all precursor and cancer lesions (123 samples), which included 45 adenoma polyps, 15 serrated polyps, 22 hyperplastic polyps and 41 adenocarcinomas, were wild-type ([Figure 1](#f1){ref-type="fig"}). Our results are in agreement with a previous report that showed the absence of *TERT* promoter mutation in colorectal adenocarcinomas ([@B11]). We also showed for the first time, that these mutations are absent in precursor lesions as well. Furthermore, it is the first study to analyze the *TERT* mutation status in Brazilian colorectal disease patients.
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Telomere length is a major tumor hallmark ([@B7]). Besides hotspot *TERT* promoter mutations, other pathways are involved with an increase in telomere length ([@B7]). One such mechanism is the alternative lengthening of telomeres (ATL) ([@B2]; [@B11]). However, a previous study reported the absence this pathway in CRC ([@B6]). Therefore, the mechanisms of telomere length variation in colorectal tumors are still unknown.

Concluding, we analyzed for the first time the presence of *TERT* promoter mutations in precursor and carcinoma colorectal lesions in Brazilian patients. The results showed the lack of *TERT* promoter mutations, suggesting that these alterations are not involved in CRC carcinogenesis.
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